•
Dec 31, 2019

Evolus Q4 2019 Earnings Report

Evolus's Q4 2019 financial results were reported, highlighted by a revenue increase and strategic business updates.

Key Takeaways

Evolus reported a net revenue of $19.5 million for Q4 2019, up from $13.2 million in Q3 2019, driven by increased Jeuveau® sales. The company's net loss improved to $14.5 million, and they exited the year with a strong cash position of $129.8 million.

Net revenue for Q4 2019 reached $19.5 million, a 48% increase from Q3 2019.

Jeuveau® achieved the number three unit share position in the U.S. market.

The company launched Evolux™, a practice loyalty program featuring co-branded digital advertising.

Net loss for Q4 2019 improved to $14.5 million due to increased sales and lower operating expenses.

Total Revenue
$19.4M
EPS
-$0.47
Previous year: -$0.46
+2.2%
GAAP Operating Expenses
$28.4M
Non-GAAP Operating Expenses
$28.2M
Non-GAAP Operating Income
-$12.4M
Gross Profit
$15.8M
Cash and Equivalents
$110M
Total Assets
$240M

Evolus

Evolus

Evolus Revenue by Segment

Forward Guidance

Evolus is increasing its focus against the fast-growing consumer segment by launching their Direct to Millennial (DTM) strategy. In Q1 2020, they launched Evolux™, and in Q2 2020, they are planning to unveil their consumer loyalty program.

Positive Outlook

  • Focus on the fast-growing millennial segment.
  • Launch of Direct to Millennial (DTM) strategy.
  • National digital campaign to accelerate consumer demand.
  • Launch of Evolux™ to deliver co-branded digital advertising to customers based on loyalty status.
  • Unveiling a consumer loyalty program in Q2 2020 to make treatments more affordable.

Revenue & Expenses

Visualization of income flow from segment revenue to net income